Suppr超能文献

大鼠甲状腺状态改变时的内皮素机制

Endothelin mechanisms in altered thyroid states in the rat.

作者信息

Rebello S, Thompson E B, Gulati A

机构信息

Department of Pharmacodynamics, University of Illinois, Chicago 60612.

出版信息

Eur J Pharmacol. 1993 Jun 11;237(1):9-16. doi: 10.1016/0014-2999(93)90086-w.

Abstract

Endothelin (ET) and its receptor characteristics were studied in hyper- and hypo-thyroid states in the rats. Hyperthyroidism was induced by daily administration of thyroxine (0.1 mg/kg i.p.) for 8 weeks, while hypothyrodism was induced by daily administration of methimazole (10 mg/kg i.p.) for 8 weeks. The chronic administration of thyroxine to rats decreased their rate of gain of body weight, increased serum T3 and T4 concentration, blood pressure and heart rate. The chronic administration of methimazole decreased the rate of gain of body weight, serum T3 and T4 concentration, blood pressure and heart rate as compared to vehicle-treated control. Plasma ET-1 levels were found to be similar in control and methimazole-treated rats, while the levels were found to be significantly (P < 0.002) increased in thyroxine-treated rats as compared to control rats. Binding studies showed that [125I]ET-1 bound to a single, high affinity binding site in the cerebral cortex, hypothalamus and pituitary. The density (Bmax) and the affinity (Kd) of [125I]ET-1 binding in the cerebral cortex and hypothalamus were found to be similar in control, methimazole- and thyroxine-treated rats. The pituitary of thyroxine-treated rats showed a decrease in the binding (34.3% decrease in the density) of [125I]ET-1 as compared to control rats. No difference was observed in the binding of [125I]ET-1 to pituitary membranes from control and methimazole-treated rats. Competition studies showed that the IC50 and Ki values of ET-3 for [125]ET-1 binding were about 8 to 11 times higher than ET-1 in cerebral cortex, hypothalamus and pituitary.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

在大鼠的甲状腺功能亢进和减退状态下研究了内皮素(ET)及其受体特性。通过每天腹腔注射甲状腺素(0.1mg/kg)持续8周诱导甲状腺功能亢进,而通过每天腹腔注射甲巯咪唑(10mg/kg)持续8周诱导甲状腺功能减退。对大鼠长期给予甲状腺素会降低其体重增加率,增加血清T3和T4浓度、血压和心率。与给予赋形剂处理的对照组相比,长期给予甲巯咪唑会降低体重增加率、血清T3和T4浓度、血压和心率。发现对照组和甲巯咪唑处理组大鼠的血浆ET-1水平相似,而与对照大鼠相比,甲状腺素处理组大鼠的ET-1水平显著升高(P<0.002)。结合研究表明,[125I]ET-1在大脑皮层、下丘脑和垂体中与单一的高亲和力结合位点结合。发现[125I]ET-1在大脑皮层和下丘脑的结合密度(Bmax)和亲和力(Kd)在对照组、甲巯咪唑处理组和甲状腺素处理组大鼠中相似。与对照大鼠相比,甲状腺素处理组大鼠的垂体显示[125I]ET-1的结合减少(密度降低34.3%)。在对照组和甲巯咪唑处理组大鼠的垂体膜上,未观察到[125I]ET-1结合的差异。竞争研究表明,在大脑皮层、下丘脑和垂体中,ET-3对[125]ET-1结合的IC50和Ki值比ET-1高约8至11倍。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验